LU86875A1 - Utilisation de l'activateur tissulaire du plasminogene,son association avec une superoxyde-dismutase et formulation pharmaceutique contenant cette association - Google Patents

Utilisation de l'activateur tissulaire du plasminogene,son association avec une superoxyde-dismutase et formulation pharmaceutique contenant cette association Download PDF

Info

Publication number
LU86875A1
LU86875A1 LU86875A LU86875A LU86875A1 LU 86875 A1 LU86875 A1 LU 86875A1 LU 86875 A LU86875 A LU 86875A LU 86875 A LU86875 A LU 86875A LU 86875 A1 LU86875 A1 LU 86875A1
Authority
LU
Luxembourg
Prior art keywords
gly
ser
leu
arg
cys
Prior art date
Application number
LU86875A
Other languages
English (en)
French (fr)
Inventor
Henry Berger Jr
Crist John Frangakis
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/862,057 external-priority patent/US4976959A/en
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of LU86875A1 publication Critical patent/LU86875A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/446—Superoxide dismutase (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21068—Tissue plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LU86875A 1986-05-12 1987-05-11 Utilisation de l'activateur tissulaire du plasminogene,son association avec une superoxyde-dismutase et formulation pharmaceutique contenant cette association LU86875A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US86204686A 1986-05-12 1986-05-12
US86205786 1986-05-12
US86204686 1986-05-12
US06/862,057 US4976959A (en) 1986-05-12 1986-05-12 T-PA and SOD in limiting tissue damage

Publications (1)

Publication Number Publication Date
LU86875A1 true LU86875A1 (fr) 1988-01-20

Family

ID=27127662

Family Applications (1)

Application Number Title Priority Date Filing Date
LU86875A LU86875A1 (fr) 1986-05-12 1987-05-11 Utilisation de l'activateur tissulaire du plasminogene,son association avec une superoxyde-dismutase et formulation pharmaceutique contenant cette association

Country Status (13)

Country Link
JP (1) JPH0680015B2 (xx)
AU (1) AU600724B2 (xx)
BE (1) BE1001425A4 (xx)
CH (1) CH672989A5 (xx)
DE (1) DE3715662A1 (xx)
DK (1) DK237187A (xx)
FR (1) FR2600895B1 (xx)
GB (1) GB2194886B (xx)
IE (1) IE59895B1 (xx)
LU (1) LU86875A1 (xx)
NL (1) NL8701113A (xx)
NZ (1) NZ220260A (xx)
SE (1) SE8701921L (xx)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0780784B2 (ja) * 1987-10-23 1995-08-30 宇部興産株式会社 微小循環障害に基づく心筋虚血傷害治療薬
NZ230808A (en) * 1988-10-24 1993-04-28 Squibb & Sons Inc Pharmaceutical compositions and combinations containing an angiotensin-converting enzyme inhibitor and a thrombolytic agent
DE4038563A1 (de) * 1990-12-04 1992-06-11 Gruenenthal Gmbh Verwendung von superoxiddismutasen zur prophylaxe und/oder behandlung von organversagen bei risikopatienten mit polytrauma
DE19518625C2 (de) * 1995-05-24 1997-08-07 Buescher Pebueso Beton Verfahren zum Abdichten von Betonrohren und ein für die Durchführung des Verfahrens geeignetes Betonrohr
US6921751B1 (en) 1998-05-20 2005-07-26 Erasmus Universiteit Rotterdam Immunoregulator
US7175679B2 (en) 2001-03-29 2007-02-13 Biotempt B.V. Oligopeptide treatment of NF-κB mediated inflammation
US8680059B2 (en) 1998-05-20 2014-03-25 Biotempt B.V. Oligopeptide acetate and formulations thereof
US20030220258A1 (en) 2001-12-21 2003-11-27 Robbert Benner Treatment of ischemic events
EP1138692A1 (en) 2000-03-29 2001-10-04 Erasmus Universiteit Rotterdam Fragments of human chorionic gonadotropin (hcg) as immunoregulator
US6844315B2 (en) 1998-05-20 2005-01-18 Erasmus Universiteit Rotterdam Immunoregulator
EP1300418A1 (en) 2001-10-04 2003-04-09 Erasmus Universiteit Rotterdam Gene regulation by oligopeptides
USRE43279E1 (en) 2000-03-29 2012-03-27 Biotemp B.V. Compositions capable of reducing elevated blood urea concentration
US7358330B2 (en) 2001-03-29 2008-04-15 Biotempt B.V. Immunoregulatory compositions
US7576174B2 (en) 2000-03-29 2009-08-18 Biotempt B.V. Compositions capable of reducing elevated blood urea concentration
US7786084B2 (en) 2001-12-21 2010-08-31 Biotempt B.V. Treatment of burns
US7501391B2 (en) 2001-12-21 2009-03-10 Biotempt B.V. Treatment of transplant survival
US7517529B2 (en) 2003-04-08 2009-04-14 Biotempt B.V. Treatment of type I diabetes
WO2007004869A2 (en) 2005-07-05 2007-01-11 Biotempt B.V. Treatment of tumors
EP1864692A1 (en) 2006-06-07 2007-12-12 Biotempt B.V. Use of peptides for the control of radiation injury
US8652476B2 (en) 2009-07-27 2014-02-18 Niigata University Pharmaceutical composition for treating ischemic events
WO2011013668A1 (ja) * 2009-07-27 2011-02-03 国立大学法人新潟大学 虚血性イベントの治療用医薬品組成物
US10617756B2 (en) 2017-01-05 2020-04-14 Shimojani, LLC Drug regimen for treatment of cerebral ischemia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8003402A (nl) * 1980-06-11 1982-01-04 Leuven Res & Dev Vzw Nieuwe plasminogeen-activator en farmaceutisch preparaat met trombolytische werking.
DE3382389D1 (de) * 1982-12-14 1991-10-02 South African Inventions Plasminogenaktivator.
JPS59196824A (ja) * 1983-04-21 1984-11-08 Kowa Co 吸着防止剤
AT391812B (de) * 1985-05-28 1990-12-10 Wellcome Found Verfahren zur herstellung einer parenteralen t-pa-loesung
US4929444A (en) * 1985-05-28 1990-05-29 Burroughs Wellcome Co. Low pH pharmaceutical formulation containing t-PA
WO1987006831A1 (en) * 1986-05-15 1987-11-19 Emory University Composition and method for treating a thrombus and embolus

Also Published As

Publication number Publication date
IE871210L (en) 1987-11-12
DK237187D0 (da) 1987-05-11
BE1001425A4 (fr) 1989-10-31
GB8711058D0 (en) 1987-06-17
DE3715662A1 (de) 1987-11-19
NL8701113A (nl) 1987-12-01
AU600724B2 (en) 1990-08-23
SE8701921L (sv) 1987-11-13
FR2600895A1 (fr) 1988-01-08
JPH0680015B2 (ja) 1994-10-12
SE8701921D0 (sv) 1987-05-11
CH672989A5 (xx) 1990-01-31
GB2194886B (en) 1990-04-25
GB2194886A (en) 1988-03-23
FR2600895B1 (fr) 1993-12-24
AU7270487A (en) 1987-11-19
IE59895B1 (en) 1994-04-20
NZ220260A (en) 1990-07-26
JPS6322026A (ja) 1988-01-29
DK237187A (da) 1987-11-13

Similar Documents

Publication Publication Date Title
BE1001425A4 (fr) Utilisation de l'activateur tissulaire du plasminogene, son association avec une superoxyde-dismutase et formulation pharmaceutique contenant cette association.
AU607303B2 (en) Composition of anticoagulants
EP0115974B1 (fr) Préparation à activité collagénolytique ayant une activité élevée et compositions pharmaceutiques la contenant
FR2593393A1 (fr) Solution aqueuse a usage parenteral d'activateur tissulaire du plasminogene, procede pour la preparer et recipient obture la contenant
LU86444A1 (fr) Nouvelle compostion d'activateur tissulaire du plasminogene
HU224826B1 (en) Activated protein c formulations
FR2591485A1 (fr) Compositions stabilisees contenant l'activateur du plasminogene du tissu humain.
US4976959A (en) T-PA and SOD in limiting tissue damage
EP2268267B1 (en) Dry transglutaminase composition
US20110053851A1 (en) Haemostasis-modulating compositions and uses therefor
EP0357296A1 (en) Combination of t-PA and protein C
FR2634125A1 (fr) Composition pharmaceutique a base de superoxyde dismutase
TW200529870A (en) Therapeutic use of factor XI
CA1282002C (en) Pharmaceutical composition comprising t-pa and oxypurinol
JP2916947B2 (ja) Ｃｐｂ―ｉの安定化方法及び製剤組成物
JP3227673B2 (ja) 膵炎予防治療薬
CN1320922C (zh) 基于用丙二烯氧合酶将脂质过氧化物酶消除的心脏保护疗法
FR2605225A1 (fr) Compositions pharmaceutiques a base d'urokinase
FR2495634A1 (fr) Enzyme nouvelle et utilisable en therapeutique
JPH05368B2 (xx)
JPH09143092A (ja) 心筋梗塞予防治療剤
FR2538702A1 (fr) Preparation a activite collagenolytique ayant une activite elevee et compositions phamaceutiques la contenant

Legal Events

Date Code Title Description
DT Application date
TA Annual fee